@Google Presents Michael Nielsen: Reinventing Discovery

If you can’t join us today at the Princeton Public Library for Michael Nielsen’s TEDx talk, I hope you enjoy this great talk for Authors@Google.

If you would like details on the PPL event tonight, click here: http://tedxsalonopensourcing.eventbrite.com/

You can also read a free excerpt from Michael’s new book Reinventing Discovery: The New Era of Networked Science here: http://press.princeton.edu/chapters/s9517.pdf

Could a video game yield a breakthrough cure for AIDS?

Alan Boyle at Cosmic Log reports on the latest example of a growing trend in open science or collaborative science. It may seem unbelievable, but he writes, “Video-game players have solved a molecular puzzle that stumped scientists for years, and those scientists say the accomplishment could point the way to crowdsourced cures for AIDS and other diseases.”

However, before Call of Duty fans use this as an excuse to log even more hours in front of the tv, the video game in question isn’t a shoot ‘em up, XBOX 360 kind of game, rather it is a game called Foldit in which players

manipulate virtual molecular structures that look like multicolored, curled-up Tinkertoy sets. The virtual molecules follow the same chemical rules that are obeyed by real molecules. When someone playing the game comes up with a more elegant structure that reflects a lower energy state for the molecule, his or her score goes up. If the structure requires more energy to maintain, or if it doesn’t reflect real-life chemistry, then the score is lower.

Researchers posted the monkey virus puzzle to Foldit as “kind of a last-ditch effort,” according to Firas Khatib, the lead author of a paper reporting these findings in Nature Structural & Molecular Biology. Not only did Foldit gamers solve the puzzle, they did so in record time — 10 days.

This feat is the latest real-world example of the power of Open Science — a new form of collaborative science that draws on “scientists” both professional and citizen and harnesses the power of the internet to collaborate over great distances. Science has traditionally rewarded solo endeavors, but increasing numbers of researchers are turning to these novel research methods.

Boyle describes the Foldit success as “a giant leap for citizen science — a burgeoning field that enlists Internet users to look for alien planets, decipher ancient texts and do other scientific tasks that sheer computer power can’t accomplish as easily.” Think you have what it takes to play Foldit and perhaps contribute to the next big medical breakthrough? You can join in the fun here: http://fold.it/

So, why does this matter to Princeton University Press? In November, we will publish the timely book Reinventing Discovery by Michael Nielsen. In the book, Nielsen, a leading proponent of Open Science, describes how the internet and crowd-sourcing are contributing to collaborative science and plots the way forward. He even has a section of the book devoted to the development of Foldit and why it is so successful. He describes concrete methods to encourage collaboration even in fields that have traditionally eschewed these forms of collaboration. If you would like to sample this book, a free excerpt is now available on our web site here: http://press.princeton.edu/chapters/s9517.pdf (PDF)

PGS Exclusive: A Parasitologist’s Weight-Loss Clinic by Eugene Kaplan

Want to lose weight? Are parasites the solution? Parasitologist and expert Eugene Kaplan looks at recent reported trends of using parasites to lose weight and discovers that all is not as it seems.

Recently it has been reported that the government of Hong Kong has had to resort to an edict against a recently popular mechanism for weight loss: swallow the parasitic roundworm, Ascaris lumbricoides, to eat some of the food you ingest and deprive you of the calories. In other words, you eat the Whopper, fries and coke and seek absolution for your sins, not in the confession box from your priest, but in the similarly dark inner recesses of your gut from a worm.

First, I am puzzled by the technique. Do you eat the eight to twelve inch adult worms in a bowl of slowly writhing noodles or do you eat the eggs in feces-contaminated bok choy? Either way, this is a serious gastronomical challenge. Not to mention, that if you opt for the eggs, they will hatch and the juveniles will migrate through your lungs before ending up in your gut.

And to further complicate things, here’s a tip. Make sure these are the human-infecting version of the worm, else the alien larva, let’s say from a similar species in a dog or cat, will get confused in its wanderings and could end up in your eye or brain.

And as if these potential complications weren’t enough, here’s the real rub: unless you swallow enough of these living noodles to clog up your intestine, they will not eat enough to deprive you of the calories that make you overweight. I can attest to this. I had an eight inch female in my intestines and didn’t feel a thing nor lose an ounce of weight. Ascaris has a relatively slow metabolism. It’s not like you have a being like the one in Alien inside you. This is just a pencil thick, eight inch weight-loss device, hardly enough to transform your body on its own.

While the use of Ascaris to lose weight may sound like the stuff of science fiction, it actually is part of a long history of parasitic weight loss. At the 1938 World’s Fair, one could buy a weight-loss pill that brazenly stated it contained “tapeworms”. This was legitimate. The pill contained the scolices (anterior end) of the human beef tapeworm which would produce a bevy of foot long ribbon-like tapeworms hanging in your upper intestine, bathed in your intestinal juices. No eating a bowl of living noodles – users just had to take a pill like any other weight-loss pill – and it was touted as a safe method of weight loss.

The catch – there is no evidence that such an infection can cause you to lose weight – common superstition notwithstanding. Unless you are in terrible physical shape – in which case you would probably be emaciated and not in need of this weight-loss program –a heavy tapeworm infection would not cause you to lose weight, but it might cause death.
A more logical idea is to purchase leeches from a leech farm (there is one in my neighborhood; I can get you the phone number). Leeches are used to suck fluids from lymph-swollen sites where an appendage was just reattached surgically and swelling threatens to burst the sutures. If you use enough leeches, say you arrange them so that they sprout from your arm like branches from a tree, they could remove enough blood to shift your weight scale to the left..

I can go on, like swallowing the cysts of the one-celled animals, Giardia or Entamoeba histolytica. The severe diarrhea would deprive you of excess water and food and leave you emaciated in a week – ads for this method could promise “rapid weight loss.” But the aforementioned techniques seem to be adequate.

And so we arrive at the end of this weight-loss clinic. While parasites might seem like a sure-fire, quick solution, perhaps it might be better to simply forego the Whopper next time.


Eugene H. Kaplan is the Donald E. Axinn Endowed Distinguished Professor of Ecology and Conservation (emeritus) at Hofstra University. His many books include What’s Eating You: People and Parasites and Sensuous Seas: Tales of a Marine Biologist. He is about to embark on a trip to Israel, perhaps stuffed pigeon will be on the menu again.

Like this article? Read Gene’s other blog posts here: Go Ahead, Try the Guinea Pig and here Climate Change is Bringing an Invasion of Parasites.

Princeton Global Science, Issue 3

You will notice we have slightly changed the way we are producing Princeton Global Science. The first two issues were published all at once on the 1st and 15th of the month, but for the past two weeks, we have posted articles as they were ready. So today, I am posting more or less a table of contents to highlight these contributions.

Paul Nahin contributes a video log about his publishing relationship with with Princeton University Press and his writing process — it turns out he writes a page a day, no matter what. Paul has written eight books for PUP and he describes the behind-the-scenes wrangling that goes into writing his books and the cover designs for three of them.

We also have a dialogue with Paul Thagard, author of The Brain and the Meaning of Life, in which he describes how a book that was originally conceived as an assessment of current research in neuroscience shifted to tackle one of the largest philosophical questions — what is the meaning of life?

Our natural history guides are a large part of our publishing program and with two new guides publishing in October, it makes sense that our Princeton Field Guide series is highlighted this issue. Science Group Publisher Robert Kirk describes the history of this popular series and we have features on the most recent additions The Princeton Field Guide to Dinosaurs by Gregory S. Paul and Parrots of the World by Joseph M. Forshaw with illustrations by Frank Knight.

Click here to view the daily dinosaur feature which draws on information and images from The Princeton Field Guide to Dinosaurs and click here for a sneak peek of the page layout and gorgeous illustrations from Parrots of the World.

As always, we also include a classic text from Princeton University Press history. This issue’s selection from A Century of Books is Finite Dimensional Vector Spaces by Paul R. Halmos.


PGS Exclusive: How the FDA Shapes Modern Science, including Cancer Therapeutics by Daniel Carpenter

Science is often portrayed as an independent activity, a calling that involves the isolation of the ivory tower and the lab. Yet in ways that we scarcely recognize, almost every facet of modern medical science is deeply shaped by the government, and in particular by the U.S. Food and Drug Administration (FDA). The very structure, procedure, methods and concepts of modern medical science – as well as the way that billions of dollars are spent – are deeply shaped by the FDA, in ways illuminated by a new Princeton book, Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA, written by Harvard professor Daniel Carpenter. Here, Carpenter reflects on how the FDA shapes modern science, specifically focusing on cancer therapeutics.



Journalists report daily on the latest results from a “Phase II” trial or a “Phase III” experiment. Yet where do these terms come from? When did we demand that medical experiments be partitioned into phases? For better or worse, these phases created the modern clinical trial industry, and they are the legacy of the FDA. Whenever scientists begin work on a drug or medical device, they must submit an experimental “protocol” that specifies what will happen not just in the next experiment, but the one after that, and the one after that. The very concepts and statistical measures used in these experiments must be approved by the FDA before any of the tests can begin. The entire world – ranging from European drug regulators and the World Health Organization to agencies and researchers in China, India, Israel and Latin America – now relies upon this phased system of experiment. But until now, no one has recognized it for what it is: the creation of an American government agency.

In terms of developing new treatments, cancer therapeutics has arguably been one of the success stories of modern medical science. Drugs like cisplatin and paclitaxel have become reliable weapons in the oncologist’s arsenal, and they have been infused into the veins of tens of millions of human beings. Yet the very terms of modern oncology – what counts as a success when treating cancer, such as tumor progression and viral load – have been shaped by what the FDA accepts as “surrogate endpoints” for a clinical trial. When the FDA decided that tumor regression counts as evidence of treatment efficacy for cancer patients, drug companies, scientists and statisticians around the world responded by tailoring their experiments, measures and statistical methods to the standard of tumor regression. The very shape of oncology was changed.

Historian of science Steven Shapin has described scientists as “struggling for credibility and authority,” and the FDA is also moved and constrained by a similar politics of legitimacy and trust. The agency’s vast power is enabled, but also limited by, its reputation. And because science and medicine rarely speak with one voice – cardiologists disagree with endocrinologists on the proper course of diabetes treatment, statisticians dissent from physicians on whether an experiment is informative or rigorous – the politics of pharmaceutical regulation depends upon a delicate equipoise among constituencies and audiences. The conflict between oncologists and FDA officials changed both the course of cancer treatment as well as the operations of regulators.

Does the FDA’s influence upon science help or hinder medical progress? This is a complicated question to which pundits and politicians have given simplistic answers. Yet talk to a scientist in the medical or biotechnology field, and they will tell you that theirs is a heavily regulated life. Any experiment with humans or animals needs to have a protocol designed in advance of the tests, needs approval by an organizational board or two (including a separate committee if human subjects are involved), is subject to inspection by federal agencies at any time, and must spell out the sequence of tests and methods used. And if the experiment involves a drug or device (and now, a tobacco product) the experiment needs assent of the U.S. Food and Drug Administration (FDA).

New historical and statistical evidence shows us that FDA decisions can scare off drug development by inducing companies and scientists to abandon their therapeutic projects. The politics of reputation can work to ameliorate or exacerbate these constraints. Some politicians, companies and disease sufferers press the agency for more rapid approval? of new therapies, while consumer advocates, other politicians and many medical professionals press the agency toward more stringent requirements upon drugs and drug experiments. In other ways, by standardizing terms and expectations, FDA regulations make scientific progress more possible. When statistical tests and physiologic measures are standardized; when scientists speak to one another with a common vocabulary that has been honed by these standards; when expectations and scientific discourse are focused upon a common protocol for a sequence of experiments – when these things happen, the basic terms of inquiry are stabilized so that effort and thought can be devoted to testing hypotheses and developing treatments. In many cases, regulation permits science to progress.



New Princeton Global Science tomorrow

Check in tomorrow for Q&As with authors Deborah M. Gordon and Tom Boellstorff. Deborah tells us what her study of ants reveals about collective behavior, while Tom describes the difficulties he encountered in conducting ethnographic research in Second Life.

Also in this edition of PGS will be exclusive articles from Dan Carpenter, author of Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA and Eugene Kaplan, author of What’s Eating You? People and Parasites.

Princeton Global Science launches September 1st

Next week we will launch Princeton Global Science on this blog. Hope you will join us on September 1st for original content from from our science editors and authors. More to come!

“Your book made me retch. And itch. Why are you so keen on parasites?” the Toronto Star gets under Eugene Kaplan’s skin

Nancy White of the Toronto Star interviews What’s Eating You? author Eugene Kaplan about his fascination with parasites. He reveals what he thinks are the worst parasites a human can get, talks about bedbugs and the impact of global warming on parasite infestations, and lastly tells the tale of a woman who was pregnant with …

(wait for it)

tapeworms.

Read the complete Q&A here.

Join the Science Book Challenge 2010

What is the Science Book Challenge you ask? Well, according to the Scienticity site:

The Science Book Challenge is easy as pi: read 3 (or 3.14!) science books during 2010, then tell us about the books you’ve read and help spread science literacy.

Sounds like an admirable pursuit and you have approximately 5 months left to complete the task. Here are some good PUP books to help you reach your goal:

The Little Book of String Theory

Steven S. Gubser

How to Find a Habitable Planet

James Kasting

What’s Eating You?: People and Parasites

Eugene H. Kaplan

Honeybee Democracy

Thomas D. Seeley
October 2010

The Princeton Field Guide to Dinosaurs

Gregory S. Paul

October 2010

Darwin in Galápagos: Footsteps to a New World

K. Thalia Grant & Gregory B. Estes

Delete: The Virtue of Forgetting in the Digital Age

Viktor Mayer-Schönberger

The Poison King: The Life and Legend of Mithradates, Rome’s Deadliest Enemy

Adrienne Mayor

On Fact and Fraud: Cautionary Tales from the Front Lines of Science

David Goodstein

“And now, my beauties, something with poison in it.” Cleopatra takes her cue from Mithradates?

Poppies will get them for sure.  At least one famous femme fatale (read: not Dorothy Gale from Kansas) probably succumbed to a lethal dose of opium and not the oft-mythologized serpent of legend.   According to Adrienne Mayor, author of National Book Award Nominee THE POISON KING, Cleopatra ingested poison before drawing her last breath.  New discussion over the Egyptian queen’s demise has stirred up some startling links to other great mixologists in history.  Whether there really was an asp involve remains to be seen but Cleopatra almost certainly took a page out of the Mithradates guide to toxins and most likely downed a potent potable on her way to eternal sleep.

Check out this Discovery News piece where PUP’s very own Mayor weighs in on the cocktail v. snake debate!  So what do you think happened?

Library Journal’s bestsellers in medicine list features two Princeton titles

Library Journal posts the best-sellers (to libraries that is) in medicine and two of our books make the list.

Coming in at #2 is Daniel Callahan’s Taming the Beloved Beast: How Medical Technology Costs Are Destroying Our Health Care System.

And #7 on the list is The Empire of Trauma: An Inquiry into the Condition of Victimhood by Didier Fassin.

We’ve Been Here Before: History and Health Reform by Colin Gordon

“We all have some experience of a feeling which comes over us occasionally, of what we are saying and doing having been said or done before,. . . .of our having been surrounded, dim ages ago, by the same faces, objects and circumstances—of  our knowing perfectly what will be said next, as if we suddenly remembered it.”

Charles Dickens, David Copperfield

Six times in the last century (most recently in the early 1990s), health reform has appeared on the national stage, only to be chased off by anxieties about state power, the promise of private alternatives, and the political clout of doctors and employers and insurers.  The results are equally notorious: We spend nearly twice as much on health care as any other country. We insure a dwindling share of the population.  And we routinely crowd the bottom of any international ranking of health outcomes.

Not surprisingly, given these familiar facts and changing of the guard in the nation’s capital, health care is once again at center stage. “From Maine to California, from business to labor, from Democrats to Republicans,” as Barack Obama waxed optimistically during the 2008 campaign, “the emergence of new and bold proposals from across the spectrum has effectively ended the debate over whether or not we should have universal health care in this country.”

Not so fast.  Despite assurances that this time things will be different—that the stakes have changed, that powerful interests are now on board, that Congress will be coddled into cooperation—there is a pall of familiar failure settling over the health care debate.  The same sense of urgency and optimism accompanied past stabs at reform, all of which were spectacular failures.  What lessons does this history offer?

Let’s be clear what we are talking about.

A lot of people (on both sides of the debate) are casually throwing around terms like “national health insurance” and “universal coverage”—but current bills before Congress propose nothing of the kind.  Until the 1950s, health insurance in the United States covered not the cost of care but the cost of not working while you were sick.  This indemnity coverage (think AFLAC) was gradually displaced by job-based “first dollar” coverage for about two-thirds of the workforce. But almost as soon as that system (at least for covered workers and their families) was in place, coverage began to retreat again.  The “managed care” revolution has used co-payments and deductibles to recreate a system of essentially catastrophic coverage, in which insurance kicks only after substantial out-of-pocket spending.

In the current climate, “health insurance” is now a pretty elastic concept.  For many it still means something akin to conventional private or public coverage.  For the right, it means virtually any private insurance product, including high-deductible plans and health savings accounts.  For employers and employees, it has come to mean almost any job-based benefit –from a collectively-bargained health plan to a pharmaceutical discount card. The meaning of “universal health care” is equally ambiguous.  In a single-payer system, both coverage and the right to coverage are universal.  In the US, even the most optimistic reforms envision a patchwork of coverage based on a variety of claims (job status, age, income).  Increasingly, universal coverage is understood to mean only universal access – a threshold satisfied by treating health premiums like home mortgage interest in the tax code.  This is the sad irony of the town hall outbursts against socialized medicine and the horror stories imported from Britain and Canada: nothing remotely resembling national health care has ever been on the table.

Don’t move furniture into a burning house.

At the root of our health crisis lies an historical accident: reliance on jobs as a means of distributing and paying for health coverage. This began as an ad hoc arrangement to evade World War II-era wage and tax regulations.  The system stuck at the war’s end because the cost of health care was minimal, the prevalence of large-firm employment offered an easy way to spread the risk, and American firms did not face competition from countries where the health care costs and risks were socialized.  We don’t live in this world anymore, but our health system does.

There is no good reason to let the distribution of jobs determine the distribution of a basic social good—an arrangement which leaves many workers uninsured, burdens insured workers (for whom a decision to switch jobs, let alone to strike out on their own, exposes themselves and their families to the capricious risk-rating of private insurers) and penalizes responsible employers whose competitors (bottom-feeders at home, firms with socialized health costs abroad) face no such costs. All of this has been hammered home in a recession marked by stark job losses and persistent health inflation: every percentage point increase in the national unemployment rate yields 1.1 million more uninsured adults; every 10 percent increase in costs pushes another 1.4 million Americans (about a third of them children) into either public programs or the growing ranks of the uninsured.

Despite all of this, reform proposals insist on propping up job-based care and half-heartedly mopping up around its edges. This ignores a couple of pretty compelling problems: For starters, job-based coverage—which is notoriously uneven, capricious, wasteful and expensive—is the problem.  As importantly, the coverage and standards of job-based care are in free fall. Only one in three workers gets health care, in their own name, from their own employer.  For those lucky enough to have coverage, the burden of higher premiums, co-payments, deductibles, and uncovered services has risen dramatically in recent years (between 2000 and 2008, for example, health insurance premiums grew over three times as fast as wages).  Fully 62 percent of personal bankruptcies in 2007 were related to medical expenses—and 80 percent of those filing were insured.

Mopping up around job-based coverage was a bad idea in 1965, when Medicare and Medicaid passed on the premise that private employers and insurers could cherry-pick the good risks and dump the rest onto public programs.  It was a bad idea in 1994, when the Clinton Plan offered up a combination of debased private coverage and tepid universalism.  And it is a worse idea today, when both the reach and the affordability of job-based coverage are in full retreat.

Sometimes half a loaf is worse than nothing.

Scratch almost any of the “health care for all” ideas floating around and you will find a long list of discrete and often disconnected proposals: “health care for kids,” “health care for students,” “health care for the employees of small businesses,” and so on.  This reflects a longstanding reluctance to take on the political or fiscal burden of displacing job-based insurance. Historically, this instrumentalism has yielded some important achievements.  Medicare not only created near universal access for the elderly, but also dramatically reduced poverty among seniors.  The State Children’s Health Insurance Program promises the same for kids.  And states (Minnesota is a good example) with expansive eligibility for their public programs have accomplished near universal coverage at modest cost.

But there has been a price.  Over the last century, arguments that some citizens  (kids, seniors, parents, veterans) are especially deserving of public insurance have also carried the implication that others are not.  As a result, the largest cadre of the currently uninsured – working parents and their families – have no real claim on public resources and no recourse but to get another job (or two). This crazy patchwork is also expensive.  It costs real money to sort the insured from the uninsured.  Public programs, by their very logic, end up with the most expensive and intractable risks.  The uninsured do get care, but often too late and in the wrong place. And, of course, all these costs are recovered in the premiums charged to private plans – encouraging employers to dump such commitments and making it less likely that anyone outside a large job-based pool can get insurance at all.

In this respect, one baseline assumption of health reform has remained unchanged since the 1930s:  We already pay for national health insurance, we just don’t get any of the benefits.  As a direct consequence of our piecemeal and incremental muddling around the edges of the health crisis, we spend as much, in public dollars, on health care as any of our democratic and industrialized peers.  We spend as much again in private dollars – for a per capita bill more than double the OECD average — and claim not much (rising uninsurance, widespread insecurity, lousy health outcomes, high business costs) in return.

And yet there is now a bipartisan (and near-religious) devotion to incremental reform, the elements of which–if it ever even gets that far—include the following: expansion of existing public programs, tighter regulation on insurance underwriting, an employer mandate (requiring some to cover workers and penalizing some who don’t), an individual mandate (requiring everyone to carry health insurance and penalizing those who don’t), subsidies for employers and/or individuals who can’t afford to buy insurance, and maybe (or maybe not) a public insurance option.

If you live in Massachusetts, Oregon, Maine, Minnesota, or Tennessee there should be an eerie ring to the this combination of hodgepodge reform and optimistic projections.  Nowhere has it worked.  None of these reform laboratories have been able to reign in costs, stem the bleeding in job-based care, or control costs.  The reason are simple.  Propping up the current system—or pushing more people into it via individual or employer mandates—does nothing to address the administrative waste, actuarial complexity, or naked profiteering that created the health care crisis in the first place.

Beware of HMO’s bearing gifts.

Much has been made in the last year of the important stakeholders who are “on board” this time around.  But this is nothing new.  Health interests—doctors, hospitals, employers, insurers—have always jockeyed around reform efforts, looking to shape or stem legislation according to their distinct (and often quite contradictory) interests.  For much of the last century, the AMA — employing a combination of professional authority, political clout, and precocious lobbying skills — lead the charge against national health insurance.  Over time, the influence of doctors was eclipsed by employers and private insurers – first cooperating against the scourge of socialized medicine, then battling each other over the costs of job-based plans.

Today, things look quite different.  The AMA spent the 1990s backing the HMO as the last best alternative to state medicine.  The results, for doctors and patients, have been disastrous – a fact which has mobilized the latter but defanged the AMA as a political force.  Employers, always torn between spreading the costs of job-based care and abandoning that responsibility altogether, are leaning toward the latter.  Insurers and drug companies are now the big dogs in the race, leading the health sector in contributions to both parties.

As importantly, none of these interests speak with one voice.  Big firms with big health care commitments (remember GM?) have always flirted with the prospect of socializing those costs.  But not so Pizza Hut or Walmart.  And the bottom feeders are increasingly calling the shots—not only through organizations like the National Federation of Independent Business but through the Chamber of Commerce as well.  Some big insurers are salivating at the prospect of an individual mandate (which would force the uninsured to buy their products) even if they are leery of the public option (which would underscore how overpriced those products are).  But many insurers are not sure that increased political oversight is worth the bargain.  And while many health professionals support broad-based reform, the AMA’s official position—that the market will heal all—has changed little since the 1980s.

Health reform has faced some formidable opponents over the last century, and has made its task that much harder trying to anticipate or pre-empt that opposition.  Fear of southern segregationists in Congress doomed much of the timid universalism of the New Deal.  Deference to the AMA virtually immobilized health reform in the 1940s and 1950s, and vastly inflated the costs of Medicaid and Medicare after 1965.  Since then, efforts to appease diverse (and often quite incompatible) interests have routinely turned good intentions into either bad policy or legislative shipwrecks.  That is clearly what happened in 1992-94, when the Clinton’s eagerness to please everyone made opponents of them all.  And that is clearly what is happening today, as Congressional reforms retreat to plan that manages to be ambitious enough to scare off the stakeholders, but modest enough to make little difference.

Don’t believe the myths.

Our current (and historical) hesitance to address the health crisis been sustained by a series of tenacious and overlapping myths about the provision of health care.  In 1917, insurance executives raised the fear of “Prussian” or “Bolshevik” medicine. In the 1940s, the AMA made up a quote from Lenin—“socialized medicine is the keystone in the arch of the socialist state”—to punctuate its Cold War campaign against public health insurance.  The same arguments, further refined in the 1992-4 debate, are being made today.  Republican pollster Frank Luntz’s now-infamous memo, “The Language of Healthcare 2009,” lays out the talking points:  any public program or option is slippery slope to “government takeover,” and national health systems (insert Canadian or British horror story here) stifle innovation, encourage malingering, and ration care—either by forcing patients to wait or pulling the plug.

Let’s examine these in turn.  The AMA and others have always raised the specter of the “moral hazard,” of describe the ways in which insurance might change the behavior of the insured.  Those who need a doctor, as the AMA argued in 1955, “will have to compete for the doctor’s time with the whole gamut of people who have only minor complaints, imaginary ailments, trivial requests, or just a desire to ‘cash in’ on whatever benefits are available.”  But this assumes that health care is a commodity like mufflers or breakfast cereal, and that people will consume more if it is cheaper.  And this is clearly not the case.  People don’t want to consume health services and their is no evidence from national health care settings that they flock to the proctologist just because its free. And, as we know from a generation of “managed competition,” making health care more expensive does not magically conjure up “responsible” consumption.  Indeed, those who have trouble affording health care put off both—making the system more expensive and less efficient for everyone.

A close analogue to this is the myth of market efficiency—best captured by the discipline supposedly imposed on patients and providers by “managed competition.” But this too is just a useful ideological illusion, because the provision of health care confounds almost all of the assumption and rules of neoclassical economics.  There is no conventional “supply” of health care, which is delivered by a tangle of professional and local monopolies.  And there is no conventional “demand” for health care.  The  top ten percent of the non-elderly population (ranked by their share of expenditures) accounts for almost two-thirds of health spending, the top five percent account for almost half, and the top one percent account for almost one quarter.  This is not a market, and its sheer folly to expect to act like one.

Perhaps the most pervasive myth—retold in different ways at hundreds of town hall meetings this summer—is that of government incompetence. Here, of course, is where the examples of Canada and Britain are actually useful.  By any measure, we spend more on health care and get less in return than any of our democratic peers.  The money squandered on administrative waste (the additional costs of running our patchwork system) alone is enough to cover all those uninsured.  Indeed the only corner of our health care system which consistently demonstrates both patient satisfaction and administrative efficiency is that which most resembles the Canadian system—Medicare.

Finally, all of this bedpan rattling about freedom and coercion tends to obscure what is really at stake.  The Clinton-era bumper sticker–”National Health Care? The Compassion of the IRS! The Efficiency of the Post Office! All at Pentagon Prices!”—got it nearly exactly wrong.   What we have now, under our patchwork system of job-based care and private insurance, is a nightmare of inflation, waste, and bureaucratic intrusion.  Unfortunately—as the opposition mobilizes and Congress retreats to incremental muddling—it looks as if real reform will be dead on arrival once again.


Colin Gordon is a professor in the history department of the University of Iowa and author of Dead on Arrival: The Politics of Health Care in Twentieth-Century America.